Maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) should reduce rates of relapse with minimal toxicity. The MAINRITSAN trial—the first randomized controlled trial to compare the efficacies of rituximab and azathioprine in AAV remission maintenance—has demonstrated a superior outcome using rituximab. These data have important implications for the management of AAV.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jennette, J. C. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65, 1–11 (2013).
Jennette, J. C. & Falk, R. J. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat. Rev. Rheumatol. 10, 463–473 (2014).
Guillevin, L. et al., Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 371, 1771–1780 (2014).
Little, M. A. et al., Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036–1043 (2010).
Tanna, A., Tam, F. W. & F. W. Pusey, C. D. B-cell-targeted therapy in adult glomerulonephritis. Expert. Opin. Biol. Ther. 13, 1691–1706 (2013).
Stone, J. H. et al., Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
Jones, R. B. et al., Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211–220 (2010).
Smith, R. M. et al., Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 3760–3769 (2012).
Cartin-Ceba, R. et al., Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 64, 3770–3778 (2012).
Pendergraft, W. F. 3rd et al., Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin. J. Am. Soc. Nephrol. 9, 736–744 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tanna, A., Pusey, C. Rituximab for maintenance of remission in AAV. Nat Rev Nephrol 11, 131–132 (2015). https://doi.org/10.1038/nrneph.2014.254
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.254
